SMS alerts can make the difference between a profitable trade and a missed opportunity.
 Text “alert” to 97000 to receive our instant, reliable and free SMS alerts.

Traders and Investors,

Today I'm focusing on a proven past winner.

The ticker is OBMP.

In fact, members will remember I first alerted OBMP on 20 January. It opened at $0.20 and hit $0.25 that same day on big volume for a 25% gain. 

Even more impressive was that it went on to breakout in a big way, hitting a six month high of $0.42 just a few weeks later, for over 100% gains from our alert price.

The next time I alerted OBMP was in March and it recorded 20% gains.

OBMP has since pulled back a long way, right above long term support levels, and closed at around $0.13 on Tuesday. I was watching level 2 and it appeared to have a ton of support at $0.10. That's why I think we see another bounce higher this week.

For those newer members, my view on OBMP remains the same, and here it is...

Biotech has and will continue to be one of the hottest sector in 2017, and it shows no signs of slowing down yet. 

Many small cap biotech's have been running 100, 200, even 1,000%+ in a matter of days.

And with a massively oversold pullback, OBMP could be the perfect biotech trade.

In addition, OBMP has excellent recent volume and liquidity, a tight level 2, and a small market cap and tiny float, a great combination for traders and investors alike.



So what's the catalyst for OBMP?

OBMP has recently been announcing some major news recently.

Just yesterday OBMP announced encouraging results from clinical trials for its licensed male fertility product Andfrt® which demonstrated a clinically meaningful benefit in treating asthenozoospermia, a medical condition defined by abnormal sperm motility.

As disclosed on May 30, 2017, the Mexican Ministry of Health (MoH) recently authorized the commercialization of Andfrt®. Upon the approval, OncBioMune, through its 100%-owned Mexican subsidiary, immediately initiated the launch of Andfrt®, joining Bekunis® for constipation and Cirkused® for stress as products marketed by OncBioMune in the Mexican market.

Last week, OBMP announced that the protocol for the Company's upcoming Phase 2 clinical trial of ProscaVax as a novel therapeutic cancer vaccine for early stage prostate cancer has been submitted to the U.S. Food and Drug Administration (FDA) for review.

In the trial, ProscaVax will be evaluated for safety, tolerability and efficacy as a treatment for patients at disease presentation who, in collaboration with their oncologist, chose to forego standard approved therapies in favor of careful monitoring for disease progression, a process known more commonly as "active surveillance."

ProscaVax is an immunotherapeutic cancer vaccine consisting of a combination of the tumor-associated antigen PSA (prostate specific antigen) with the biological adjuvants interleukin-2 (IL-2) and granulocyte-macrophage colony-stimulating factor (GM-CSF).

Also last week, the Company reported that May sales in Mexico of its licensed over-the-counter product Bekunis® for constipation reached a record monthly total of approximately US$96,000.

As disclosed on March 27, 2017, sales for the first six months since the launch of Bekunis® and Cirkused® (for stress) in Mexico totaled approximately US$330,000, with Bekunis® representing the lion's share of sales. With the strong month of May for Bekunis® alone, OncBioMune is confident that it will meet or exceed its 2017 sales goal for the products in the range of US$750,000 to US$850,000.

These are some impressive and major catalysts for a company with a market cap of less than $20m and a tiny float of just $1.2m.


OncBioMune Pharmaceuticals (OBMP) is a clinical and revenue stage biopharmaceutical company engaged in the development of novel and targeted cancer therapies and a proprietary vaccine technology and commercialization of a portfolio of products internationally. Their proprietary Vaccine Technology that is designed to stimulate the immune system to attack its own cancer while not hurting the patient.

The Company's lead product, ProscaVax™ for prostate cancer, is near conclusion of a Phase 1 trial funded by the Department of Defense Navy Cancer Vaccine Program.  Based upon data showing ProscaVax is non-toxic and can lower PSA levels, they are moving ProscaVax into a Phase 2 trial for prostate cancer patients in the “Active Surveillance” category, an early stage of disease for which there are currently no treatments without significant morbidities. 

OncBioMune also has a portfolio of targeted therapies, some of which are biosimilars to blockbuster drugs. 

The prostate cancer market is a $7.1B market right now, and unfortunately one that is growing fast. OBMP is a company that could have an answer . The company's recent press releases are a signal to the world that the company has arrived, and is rapidly gaining traction on finding a much needed solution for this terrible disease.


In Conclusion...

We urge you to get OBMP on your screen now and do your research. There is plenty of information on their website and around the internet, including Yahoo! Finance and many other finance portals.

OBMP has plenty of catalysts on its side. With an oversold chart, great recent liquidity and volume, a tight level 2, major recent catalysts and an extremely hot sector, this is and could continue to be the perfect trading storm.

I'll be back in the morning with a further update.
 

 

Remember our key trading rules when trading. Capital preservation is key. Keep your stops tight, and if things don't go your way, cut your losses and look for another opportunity.